EUROPE
FACT
• One of the first biotechnology companies in Israel
• BTG supports the growing number of startups in the country
• BTG develops , produces and markets growth hormone Somatropin , EUFLEXXA for osteoarthritis sufferers , Biolin for ophthalmic surgeries and Recovelle for fertility treatment
• Recognised by the Israeli Ministry of Health for its commitment and unwavering focus on delivering high quality pharmaceuticals
• The company has received a $ 15mn from its parent company , Ferring Pharmaceuticals to expand its production capabilities focus is the manufacturing of fertility treatment Rekovelle , which will cater to ongoing global demands . “ This product is going to be manufactured at several sites at Ferring , and we will also have a backup site in Switzerland . This investment will enable us to enhance the biotech process in bio reactors and the product is derived from mammalian cells ,” says Ben Dror .
However , communication across the organisation will remain a global challenge across the business . Supplying over 40 countries , BTG has worked to build trust and transparency , and regularly meets with all involved parties to guarantee mutually beneficial relationships . “ It is important to be clear with our messages and to be very transparent with the information given to highlight that we are in this together ,” Ben Dror adds .
“ Another challenge is that in many cases we have only one supplier . It is therefore important for us to maintain this relationship with suppliers and make them partners . This creates an environment where the supplier will also experience success . The supplier is crucial to the success of our organisation .”
METHODOLOGY OF SAFETY
Additionally , in such a high cost , and highly
131 www . supplychaindigital . com